# ClearNote Health

> ClearNote Health is a San Diego molecular diagnostics company building non-invasive, blood-based tests that detect high-mortality cancers early, when treatment works best. Spun out of Stephen Quake's Stanford lab in 2016 (originally as Bluestar Genomics), it pairs a proprietary 5-hydroxymethylcytosine (5hmC) epigenomic platform with cell-free DNA analysis and machine learning. Its flagship Avantect Pancreatic Cancer Test targets high-risk patients - including adults 50+ newly diagnosed with type 2 diabetes - and the company is extending the approach to ovarian and multi-cancer detection.

- **Founded:** 2016
- **Headquarters:** San Diego, California, United States
- **Founders:** Stephen Quake (Founder (Stanford lab origin); company founded as Bluestar Genomics in 2016)
- **Team size:** ~55 employees
- **Products:** Avantect Pancreatic Cancer Test, Avantect Ovarian Cancer Test, Avantect Multi-Cancer Detection Test, Epigenomics / Virtuoso Platform for Biopharma
- **Notable:** FDA Breakthrough Device Designation (2021), CAP accreditation for its clinical laboratory (2022), Rebranded from Bluestar Genomics to ClearNote Health (2022)

## Products & services

- **Avantect Pancreatic Cancer Test** — A non-invasive blood test for patients at elevated risk of pancreatic cancer, including those age 50+ newly diagnosed with type 2 diabetes, with a family history, or known genetic predisposition. The enhanced version combines 5hmC epigenomic patterns, cell-free DNA genomic/genotyping data, and a glycan biomarker with machine learning, reporting 82.6% sensitivity and 97.5% specificity (76.8% sensitivity for stage I-II).
- **Avantect Ovarian Cancer Test** — A blood-based early detection test for ovarian cancer, a high-mortality disease usually found late. Received a CPT code and CMS preliminary payment recommendation in 2024.
- **Avantect Multi-Cancer Detection Test** — A multi-cancer early detection assay selected as one of two non-invasive blood-based technologies for the National Cancer Institute's Vanguard Study (2025).
- **Epigenomics / Virtuoso Platform for Biopharma** — A 5hmC epigenomic and cell-free DNA platform offered to pharmaceutical and research partners for biomarker discovery and drug development.

## Achievements

- FDA Breakthrough Device Designation (2021)
- CAP accreditation for its clinical laboratory (2022)
- Rebranded from Bluestar Genomics to ClearNote Health (2022)
- Avantect Ovarian Cancer Test received CPT code and CMS preliminary payment recommendation (2024)
- Avantect Multi-Cancer Detection Test selected for NCI Vanguard Study (2025)
- New York State Department of Health approval for Avantect Pancreatic Cancer Test (Feb 2025)
- First in vitro diagnostic approval / UKCA marking for the Avantect Pancreatic Cancer Test (July 2025)
- Enhanced Avantect Pancreatic Cancer Test reporting 82.6% sensitivity and 97.5% specificity (2026)
- Closed $52M Series D financing (May 2026)

## Latest updates

- **2026-05** — Secured $52M Series D financing and strengthened its leadership team to accelerate growth in early cancer detection.
- **2026-02** — Launched enhanced Avantect Pancreatic Cancer Test with 82.6% sensitivity and 97.5% specificity in high-risk populations.
- **2025-07** — Received first in vitro diagnostic approval (UKCA marking) for the Avantect Pancreatic Cancer Test.
- **2025-02** — Earned New York State Department of Health approval for the Avantect Pancreatic Cancer Test.
- **2025-01** — Avantect Multi-Cancer Detection Test selected for the National Cancer Institute's Vanguard Study.
- **2024-09** — Avantect Ovarian Cancer Test received a CPT code and CMS preliminary payment recommendation.
- **2024-01** — Announced partnership with Personalis to distribute its 5hmC epigenomic platform for biopharma.

## Links

- Website: https://clearnotehealth.com
- LinkedIn: https://www.linkedin.com/company/clearnotehealth
- Twitter/X: https://twitter.com/ClearNoteHealth

---

Profile page: https://yespress.io/clearnote-health
Published by YesPress — https://yespress.io
Last updated: 2026-06-15